Associated Papers
Insights into the role of JAK2-I724T variant in myeloproliferative neoplasms from a unique cohort of New Zealand patients.
Puli'uvea C et al.
Hematology (amsterdam, Netherlands), 2024
Diagnosis- and Prognosis-Related Gene Alterations in BCR::ABL1-Negative Myeloproliferative Neoplasms.
Morishita S et al.
International Journal of Molecular Sciences, 2023
37629188 (PubMed )
Supplement: ijms-24-13008-s001.zip › ijms-2555672-supplementary.pdf
Functional analysis of atypical mutations in exons 13 and 15 of JAK2 gene in myeloproliferative neoplasms.
Luo M et al.
International Journal of Laboratory Hematology, 2021
Selective Janus Kinase 2 (JAK2) Pseudokinase Ligands with a Diaminotriazole Core.
Liosi ME et al.
Journal of Medicinal Chemistry, 2020
A resequencing program in India detects the rare JAK2 L579F mutation in patients suffering from polycythemia vera and negative for JAK2 V617F.
Acharya A et al.
International Journal of Laboratory Hematology, 2014
Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.
Jatiani SS et al.
Genes & Cancer, 2010
Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations.
Lee TS et al.
Bmc Structural Biology, 2009
Select a paper to view details